- Home
- GPI vs RARE Comparison
GPI vs RARE Comparison
Compare GPI & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPI
- RARE
- Stock Information
- Founded
- GPI 1995
- RARE 2010
- Country
- GPI United States
- RARE United States
- Employees
- GPI N/A
- RARE N/A
- Industry
- GPI Retail-Auto Dealers and Gas Stations
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- GPI Consumer Discretionary
- RARE Health Care
- Exchange
- GPI Nasdaq
- RARE Nasdaq
- Market Cap
- GPI 5.1B
- RARE 5.2B
- IPO Year
- GPI 1997
- RARE 2014
- Fundamental
- Price
- GPI $410.00
- RARE $46.51
- Analyst Decision
- GPI Buy
- RARE Strong Buy
- Analyst Count
- GPI 6
- RARE 14
- Target Price
- GPI $386.50
- RARE $86.79
- AVG Volume (30 Days)
- GPI 144.3K
- RARE 947.6K
- Earning Date
- GPI 10-30-2024
- RARE 11-05-2024
- Dividend Yield
- GPI 0.47%
- RARE N/A
- EPS Growth
- GPI N/A
- RARE N/A
- EPS
- GPI 37.54
- RARE N/A
- Revenue
- GPI $18,868,200,000.00
- RARE $522,745,000.00
- Revenue This Year
- GPI $10.56
- RARE $27.29
- Revenue Next Year
- GPI $11.42
- RARE $18.30
- P/E Ratio
- GPI $10.71
- RARE N/A
- Revenue Growth
- GPI 8.05
- RARE 27.44
- 52 Week Low
- GPI $255.73
- RARE $37.02
- 52 Week High
- GPI $422.28
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- GPI 57.21
- RARE 36.73
- Support Level
- GPI $395.15
- RARE $43.04
- Resistance Level
- GPI $417.07
- RARE $46.98
- Average True Range (ATR)
- GPI 10.86
- RARE 2.11
- MACD
- GPI 0.01
- RARE -0.31
- Stochastic Oscillator
- GPI 64.36
- RARE 34.47
About GPI Group 1 Automotive Inc.
As of July, Group 1 owns and operates 42 collision centers and 206 automotive dealerships in the us and the UK, offering 35 brands of automobiles altogether. About 150 of the stores are in the us with locations mostly in metropolitan areas in 17 states in the Northeast, Southeast, Midwest, and California. Texas alone contributed 38% of new-vehicle unit volume in 2023 and the UK about 19%. Texas, Oklahoma, and Massachusetts combined was 53%. Revenue in 2023 totaled $17.9 billion. The Inchcape UK deal should close in third-quarter 2024 and add nearly $3 billion of annual revenue. That deal will bring the UK store count to over 110. The company was founded in 1995 and is based in Houston.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.